| APSAC | acylated plasminogen-streptokinase activator complex; anisoylated plasminogen streptokinase activato... |
|---|---|
| APSAC | 1) Acylating the Plasminogen Streptokinase Activated Complex 2) Anisoylat... |
| PAI | patient assessment instrument; plasminogen activator inhibitor |
| PAI-1 | plasminogen-activator inhibitor-1 |
| TPAI | tissue plasminogen activator inhibitor |
| PAI 1 | Plasminogen Activator Inhibitor type 1 |
|---|---|
| PAI-2 | Plasminogen activator inhibitor 2 |
| PAI | Plasminogen activator inhibitor activity |
| PAI-2 | Plasminogen activator inhibitor type 2 |
| PAI-1 | plasminogen activator and its inhibitor |
| plasminogen activator inhibitor 1 | <chemical> A member of the serpin family of proteins. It inhibits both the tissue-type and urokinase-type plasminogen activator. Pharmacological action: serine proteinase inhibitors. (12 Dec 1998) |
|---|---|
| plasminogen activator inhibitor 2 | <chemical> Member of the serpin family of proteins. It inhibits both the tissue-type and urokinase-type plasminogen activator. Pharmacological action: serine proteinase inhibitors. (12 Dec 1998) |
| plasminogen activator | <enzyme> Serine protease that acts on plasminogen to generate plasmin. Has also been implicated in invasiveness and is produced by many normal and invasive cells. The vascular form (tPA, 55 kD) is very similar to tissue plasminogen activator (uPA, 70 kD) and to streptokinase and urokinase. (18 Nov 1997) |
|---|---|
| tissue plasminogen activator | <enzyme> Plasma serine protease, one of a closely related group of plasminogen activators. Contains an EGF like domain and multiple copies of the kringle domain. (18 Nov 1997) |
| kidney plasminogen activator | <protein> A precursor to the enzyme urokinase that has blood clotting properties. (14 Nov 1997) |
| plasminogen | <enzyme> The inactive precursor of plasmin. (18 Nov 1997) |
| plasminogen inactivators | <chemical> Important modulators of the activity of plasminogen activator. Four inhibitors, all belonging to the serpin family of proteins, have been implicated in plasminogen activation inhibition. They are pai-1, pai-2, protease-nexin, and protein c inhibitor (pai-3). All inhibit both the tissue-type and urokinase-type plasminogen activator. Pharmacological action: serine proteinase inhibitors. (12 Dec 1998) |
| activator | <biochemistry> A DNA-binding transcription metabolite that positively modulates an allosteric enzyme or regulates one or more genes by increasing the rate of transcription. (12 Mar 1998) |
| activator appliances | Loose-fitting removable orthodontic appliances which redirect the pressures of the facial and masticatory muscles onto the teeth and their supporting structures to produce improvements in tooth arrangements and occlusal relations. (12 Dec 1998) |
| catabolite gene activator | catabolite (gene) activator protein |
| catabolite gene activator protein | <molecular biology, protein> A regulatory protein that triggers the transcription of genes that generate the enzymes bacteria need to usenutrients when glucose isabsent. (16 Mar 1998) |
| catabolite (gene) activator protein | A protein that can be activated by cAMP, whereupon it affects the action of RNA polymerase by binding it with it or near it on the DNA to be transcribed. Synonym: cAMP receptor protein, catabolite gene activator. (05 Mar 2000) |
| polyclonal activator | A substance that will activate T-cells, B-cells, or both regardless of their specificities. (05 Mar 2000) |
| protein activator, aminolevulinic acid synthetase | <chemical> From rat liver mitochondria Synonym: aminolevulinic acid synthetase activator (26 Jun 1999) |
| a1-trypsin inhibitor | A glycoprotein that is the major protease inhibitor of human serum, is synthesised in the liver, and is genetically polymorphic due to the presence of over 20 alleles; individuals appropriately homozygous are deficient in a1-trypsin and are predisposed to pulmonary emphysema and juvenile hepatic cirrhosis because of alterations in the amino acid and sialic acid components of the glycoprotein. A1-Antitrypsin also inhibits thrombin. Synonym: a1-trypsin inhibitor, human a1-proteinase inhibitor. (05 Mar 2000) |
| ACE inhibitor | <pharmacology> A group of antihypertensive medications that work by inhibiting an enzyme (angiotensin-converting enzyme) that is important in the regulation of blood pressure. Studies have also indicated that it may help prevent or slow the progression of kidney disease in patients with diabetes. Examples include: captopril, ramipril, enalapril, losartan potassium, bepridil and lisinopril. (12 Mar 1998) |
| aldose reductase inhibitor | <pharmacology> A class of drugs being studied as a way to prevent eye and nerve damage in people with diabetes. Aldose reductase is an enzyme that is normally present in the eye and in many other parts of the body. It helps change glucose (sugar) into a sugar alcohol called sorbitol. Too much sorbitol trapped in eye and nerve cells can damage these cells, leading to retinopathy and neuropathy. Drugs that prevent or slow (inhibit) the action of aldose reductase are being studied as a way to prevent or delay these complications of diabetes. (09 Oct 1997) |
Synonyms : Type 1 Plasminogen Activator Inhibitor
Synonyms : Type 2 Plasminogen Activator Inhibitor
| plasminogen activator inhibitor-1 |
A protein that degrades extracellular tissues. It has been linked to the invasive and metastatic spread of cancers.
출처:
|
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|